US EditionU.S. Reaches Deal with U.K. on Higher Drug Prices
The U.K. will pay 25% more for new medicines to avoid U.S. tariffs and boost pharmaceutical investment, reversing NHS spending declines, officials said.
- A bilateral deal sets new pricing and tariff terms, with the United Kingdom agreeing to pay 25% more for new medicines and the U.S. confirming a 0% tariff rate for three years.
- Under U.S. tariff pressure and President Donald Trump's push to have other nations pay more for pharmaceuticals, negotiators aimed to reverse a decade-long NHS spending decline on innovative medicines.
- The U.K. committed to preventing higher new-drug prices from being materially eroded, while Chris Klomp confirmed the repayment rate will stay at or below 15%.
- British officials highlighted benefits for the United Kingdom, while United States officials said the agreement will strengthen supply chains, create high-quality jobs and reinforce life-sciences investment.
- Tied to the MFN policy, the deal comes less than two months after President Donald Trump announced the first results of his most-favored-nation pharmaceutical drug pricing policy, with U.S. officials framing it as stopping American patients from subsidizing prescription drugs abroad.
35 Articles
35 Articles
Higher Drug Prices, No Tariffs: U.K. Trade Pact Shows How Trump Is Coaxing Countries to Pay More for Meds
The U.K. cost-effectiveness standard for drugs will increase by 25% in exchange for zero tariffs on the country’s pharmaceutical exports. The new trade agreement’s parameters could shape deals the Trump administration is pursuing with other countries. The post Higher Drug Prices, No Tariffs: U.K. Trade Pact Shows How Trump Is Coaxing Countries to Pay More for Meds appeared first on MedCity News.
US, UK finalize pharma pricing deal to boost innovation
The basics: US–UK deal raises United Kingdom payments for innovative medicines by 25% VPAG repayment rates fall to 15% starting in 2026 US grants tariff exemptions, limits future pricing actions NJ life sciences leaders say the agreement supports innovation and investment The United States and the United Kingdom reached an agreement in principle on pharmaceutical pricing. The update comes as part of the U.S.–U.K. Economic Prosperity Deal (EPD),…
UK hikes drug prices after pharma exodus - European Biotechnology Magazine
After the withdrawal of investment pledges totalling £2bn by pharmaceutical companies — seeking to offset lower US revenue by raising UK prices — the British government has now caved in and signed a deal with the US administration that will lift UK drug prices by 25% UK hikes drug prices after £2bn pharma investment flight. Trade deal lifts NICE caps; US waives tariffs and patents rise 25%—British patients pay
Coverage Details
Bias Distribution
- 41% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
